We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals

177 hedge funds and large institutions have $396M invested in Vanda Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 67 increasing their positions, 60 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more capital inflows, than outflows

Capital inflows: $77.3M | Capital outflows: $38.5M

12% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 60

9.54% more ownership

Funds ownership: 93.01% → 102.55% (+9.5%)

6% less funds holding

Funds holding: 189 → 177 (-12)

34% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 32

48% less call options, than puts

Call options by funds: $17K | Put options by funds: $33K

Holders
177
Holders Change
-12
Holders Change %
-6.35%
% of All Funds
2.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
67
Reduced
60
Closed
32
Calls
$17K
Puts
$33K
Net Calls
-$16K
Net Calls Change
+$50K

VNDA Hedge Fund Activity: Q1 2023 in Review

177 of the 6,291 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2023, worth a combined $396M — up 1.8% from $389M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of VNDA and 21 opened new positions — a net loss of 11 holders — while 60 trimmed existing stakes and 67 added.

The largest buyer was Bank of America, adding an estimated $9.46M. The largest seller was Macquarie Group, exiting entirely with an estimated $9.8M sold.

  • 177 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2023, down from 189 in Q4 2022.
  • Funds reported $396M of Vanda Pharmaceuticals stock for Q1 2023, up 1.8% quarter-over-quarter.
  • 21 funds opened new Vanda Pharmaceuticals positions in Q1 2023 and 32 closed out, a net change of -11 holders.
  • The largest Vanda Pharmaceuticals buyer in Q1 2023 was Bank of America, an estimated $9.46M added.
  • The largest Vanda Pharmaceuticals seller in Q1 2023 was Macquarie Group, an estimated $9.8M sold.

Based on aggregated 13F filings for Q1 2023.